{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:12:47Z","timestamp":1783948367613,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02320-2","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:45:18Z","timestamp":1777088718000},"page":"1141-1145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pixavir Marboxil: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"2","key":"2320_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.amjms.2025.10.010","volume":"371","author":"A Hannaford","year":"2026","unstructured":"Hannaford A, Aleissa M, Sherman AC. Update on influenza. Am J Med Sci. 2026;371(2):124\u201332.","journal-title":"Am J Med Sci"},{"key":"2320_CR2","unstructured":"Taigen Biotech. PIXAVIR MARBOXIL: new antiviral drug for influenza TG-1000. 2026. https:\/\/www.taigenbiotech.com\/tw\/product\/. Accessed 30 Mar 2026."},{"key":"2320_CR3","unstructured":"Joincare Pharmaceutical Group Industry Co. Ltd. Pixavir marboxil capsules (Yilikang\u00ae), for oral use: Chinese prescribing information. 2025. https:\/\/zy.yaozh.com\/instruct\/sms20260326\/wj202604011611.pdf. Accessed 30 Mar 2026."},{"key":"2320_CR4","unstructured":"TaiGen Biotechnology. Taigen's pixavir receives NMPA approval in China, targets influenza market [media release]. 11 Dec 2025. https:\/\/www.taigenbiotech.com\/en\/news\/detail\/225."},{"key":"2320_CR5","unstructured":"TaiGen Biotechnology. TaiGen enters exclusive license agreement with Joincare for TG-1000 in China [media release]. 22 Mar 2023. https:\/\/www.taigenbiotech.com\/en\/news\/detail\/214."},{"key":"2320_CR6","unstructured":"TaiGen Biotechnology. TaiGen licenses antiviral pixavir marboxil in India [media release]. 23 Oct 2025. https:\/\/www.taigenbiotech.com\/en\/news\/detail\/223."},{"key":"2320_CR7","unstructured":"TaiGen Biotechnology. TaiGen licenses influenza antiviral to South Korea\u2019s Boryung Biopharma [media release]. 26 Jan 2026. https:\/\/www.taigenbiotech.com\/en\/news\/detail\/226."},{"key":"2320_CR8","unstructured":"TaiGen Biotechnology. TaiGen's new influenza drug TG-1000 has been granted its first US patent, adding to the benefits of licensing negotiations [media release]. 14 Jan 2020. https:\/\/www.taigenbiotech.com\/tw\/news\/detail\/18."},{"key":"2320_CR9","unstructured":"AdisInsight. Pixavir marboxil - TaiGen Biotechnology. 2026. https:\/\/adisinsight.springer.com\/drugs\/800050736. Accessed 30 Mar 2026."},{"key":"2320_CR10","unstructured":"Joincare Pharmaceutical Group Industry Co. Ltd. Pixavir marboxil: key data fact sheet [data on file]. 2026"},{"key":"2320_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1272466","volume":"14","author":"SM Xu","year":"2023","unstructured":"Xu SM, Chang LW, Tsai CY, et al. Safety, tolerability, and pharmacokinetics of TG-1000, a new molecular entity against influenza virus: first-in-human study. Front Pharmacol. 2023;14:1272466.","journal-title":"Front Pharmacol"},{"key":"2320_CR12","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.5038368","author":"F Jin","year":"2024","unstructured":"Jin F, Ye F, Ding B, et al. The efficacy and safety of a cap-dependent endonuclease inhibitor, TG-1000, in adolescent and adult outpatients with acute uncomplicated influenza: a multicenter, randomized, placebo-controlled phase III trial. SSRN. 2024. https:\/\/doi.org\/10.2139\/ssrn.5038368.","journal-title":"SSRN"},{"key":"2320_CR13","unstructured":"Wu Y. Efficacy of pixavir marboxil in influenza patients with high fever: a post hoc analysis of a phase III randomized, placebo-controlled trial [abstract no. 20250925_242782]. In: 26th academic conference of internal medicine of the Chinese Medical Association. 8\u20139 Nov 2025."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02320-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02320-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02320-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:42:25Z","timestamp":1783946545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02320-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2320"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02320-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}